financetom
Business
financetom
/
Business
/
Tata Steel’s TV Narendran says steel consumption should reflect India’s GDP growth rate
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tata Steel’s TV Narendran says steel consumption should reflect India’s GDP growth rate
Apr 12, 2023 1:31 AM

The Indian economy is looking good because of its focus on infrastructure at a time when many other global economies look fragile, Managing Director of Tata Steel CEO TV Narendran said on April 12.

Share Market Live

NSE

In an exclusive interaction with CNBC-TV18, Narendran said steel consumption should reflect in the GDP growth rate, which also depends on capacities that companies build. He said Tata Steel is in the midst of a 5 MT expansion which is likely to be completed this financial year and shall benefit the company in the next fiscal.

He stressed on the need for hydrogen to be available in plenty and priced appropriately for it to become a substitute for coal. He believes it won't make economic sense unless green hydrogen is available at less than $2/kilo.

Also Read: Here is why analysts are betting big on the metals sector

With a costly and complex transition process involved, he said the industry needs to be encouraged in a direction which will need a huge capital deployment, leading to a rise in operating costs.

On Tata Steel's European operations not faring well in FY 23, he said it continues to be a bit of a challenge though things have improved with a fall in gas prices. He added that the situation is better in India too with a fall in electricity prices and improvement in steel prices. As Tata Steel has realigned one of its blast furnaces in the Netherlands, he said that the impact will play out in the April to June quarter as well, though Narendran expects the second half of the year to be better.

Pointing to the need to look at FTAs and the associated consequences on the Indian industry, he said many FTAs signed in the past had led to more steel imports than exports, while supporting more steel exports from India.

Also Read: With China opening up, low of steel prices may be behind us, says Tata Steel CFO

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AAR Signs Multiyear Deal to Supply CFM56-5B Engine Surplus Material to Cebu Pacific
AAR Signs Multiyear Deal to Supply CFM56-5B Engine Surplus Material to Cebu Pacific
Mar 20, 2024
10:59 AM EDT, 03/20/2024 (MT Newswires) -- AAR (AIR) said Wednesday it has a multiyear agreement to provide surplus material for the CFM56-5B engine to Cebu Pacific. Financial details weren't disclosed. Under the accord, AAR said it will assist with the 30 scheduled shop visits for CFM56-5B engines that Cebu Pacific has scheduled throughout the contract period. Shares of ARR...
New Fortress Energy Closes on Purchase of Electricity Supply Contract in Brazil
New Fortress Energy Closes on Purchase of Electricity Supply Contract in Brazil
Mar 20, 2024
11:00 AM EDT, 03/20/2024 (MT Newswires) -- New Fortress Energy ( NFE ) said Wednesday it has completed its acquisition of a 1.6-gigawatt capacity reserve electricity contract from a portfolio company of private equity firm Denham Capital. Under terms of the purchase agreement, New Fortress will issue a undisclosed amount of its series A convertible preferred stock to Denham Capital...
Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy
Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy
Mar 20, 2024
11:01 AM EDT, 03/20/2024 (MT Newswires) -- Celularity ( CELU ) said Wednesday it submitted an application to the US Food and Drug Administration requesting an orphan drug designation for PDA-002 as a treatment for genetic muscle disorder facioscapulohumeral muscular dystrophy. The FDA has already approved the investigative new drug application for PDA-002 and Celularity ( CELU ) will start...
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment
Mar 20, 2024
10:57 AM EDT, 03/20/2024 (MT Newswires) -- Cabaletta Bio ( CABA ) said Wednesday the US Food and Drug Administration has given orphan drug designation to CABA-201 to potentially treat systemic sclerosis. The candidate drug is being developed to treat autoimmune diseases driven by B cells, the company said, adding the clinical trial program has four phase 1/2 trials to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved